This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Nexstim Management

Management criteria checks 1/4

Key information

Mikko Karvinen

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	3.2yrs
CEO ownership	0.1%
Management average tenure	no data
Board average tenure	3.4yrs

Recent management updates

Recent updates

CEO

Mikko Karvinen (46 yo)

3.2yrs

Tenure

Mr. Mikko Karvinen, M.Sc. (Econ.), serves as Chief Executive Officer at Nexstim Plc since June 16, 2020 and also served as an Interim Chief Executive Officer at Nexstim Plc since February 11, 2020 until Ju...

Board Members

Name	Position	Tenure	Compensation	Ownership
Martin Forss	Independent Member of the Board	3.4yrs	no data	0.12% € 357.7k
Alvaro Pascual-Leone	Member of Scientific Advisory Board	4yrs	no data	no data
Leena Niemisto	Chairman of the Board	3.4yrs	no data	0.028% € 80.3k
Timo Hilden	Independent Director	1.9yrs	no data	0.023% € 65.0k
Linda Carpenter	Member of Scientific Advisory Board	4yrs	no data	no data
Turo Nurmikko	Member of Scientific Advisory Board	4yrs	no data	no data
Tero Weckroth	Independent Director	1.9yrs	no data	0.23% € 662.9k

3.4yrs

Average Tenure

60yo

Average Age

Experienced Board: NXTMS's board of directors are considered experienced (3.4 years average tenure).

This company listing is no longer active

Nexstim Management

Management criteria checks 1/4

Key information

Recent management updates

Nexstim Plc, Annual General Meeting, Mar 31, 2023

Nexstim plc Appoints Tero Weckroth as A New Member of the Nomination Committee

High number of new and inexperienced directors

High number of new and inexperienced directors

Rohan Hoare and Tomas Holmberg No Longer Be Available to Nexstim Plc's Board of Directors for the Period 2021-2022

Recent updates

Nexstim Applies for Delisting Regarding the Secondary Listing of its Shares from Nasdaq First North Growth Market Sweden

Nexstim Plc, Annual General Meeting, Mar 31, 2023

Nexstim Reports Excellent Treatment Outcomes of over 400 MDD Patients in Patient Registry

Nexstim plc Appoints Tero Weckroth as A New Member of the Nomination Committee

First half 2022 earnings released

Nexstim Plc Provides Earnings Guidance for the Year 2022

High number of new and inexperienced directors

High number of new and inexperienced directors

Forecast to breakeven in 2022

Forecast to breakeven in 2022

Full year 2021 earnings: Revenues exceed analyst expectations

Nexstim Reaches Over 300 Completed Treatment Sessions – Continues to Report a Remission Rate Greater than 50% of MDD Patients in the Patient Registry

Nexstim Plc Announces Results of the Pilot Study in Chronic Pain Treatment At Helsinki University Hospital

Nexstim Plc Receives System Orders from Existing Hospital Customers in Finland

Nexstim Announces Continuation of Pilot Study in Treatment of Severe Depression at Kuopio University Hospital

First half 2021 earnings released: €0.17 loss per share (vs €1.25 loss in 1H 2020)

Nexstim Plc Provides Update on Pilot Study in Chronic Pain Treatment at Helsinki University Hospital

Nexstim Plc Continues to Report Very Promising MDD Treatment Outcomes with Remission Rate Greater Than 50%

Nexstim Plc Granted Authorization for Commercial Distribution of NBS System in Australia

Nexstim Gives an Update on its Promising Treatment Results of Major Depressive Disorder

Nexstim plc Receives Two NBS System Orders from Hospitals in Norway and the Us

Nexstim plc Provides Encouraging Results of the Initial Pilot Study in Severe Depression At Kuopio University Hospital

Full year 2020 earnings released

Revenue beats expectations

New 90-day high: kr1.02

German University Hospital Orders Nexstim NBS System with NexSpeech

Rohan Hoare and Tomas Holmberg No Longer Be Available to Nexstim Plc's Board of Directors for the Period 2021-2022

New 90-day high: kr1.01

Nexstim plc Receives Three New NBS System Orders

New 90-day high: kr0.69

Nexstim Plc Receives Two New NBT® System Purchase Orders in the United States

Nexstim plc Provides an Update on the Pilot Study in Severe Depression At Kuopio University Hospital

Nexstim Plc Receives an Order and Signs Purchase Agreement to Develop Two Prototype Systems Enabling Introduction of Novel Research Tool for Probing and Diagnosing the Brain

Nexstim plc Continues to Report Promising Results in Quickly Growing Number of Patients Completing SmartFocus rTMS Treatment of Major Depressive Disorder

New 90-day high: kr0.41

Pilot Study for New Depression Treatment Protocol with Nexstim NBT® System Starts in Kuopio University Hospital

New 90-day high - kr0.29

Earnings released

CEO

Tenure

Board Members

Average Tenure

Average Age